A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus
mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic
castration-refractory prostate cancer following disease progression or intolerance on
docetaxel-based chemotherapy.